Somatic mutations of a specific type (substitutions of C with T or G in TCA or TCT motifs) have been described in many tumors as APOBECsignature mutations [1][2] [3] [4] [5] . These mutations are generated by the cytidine deaminase activity of proteins belonging to the apolipoprotein B mRNA editing enzyme, catalytic-polypeptide-like (APOBEC) family 6, 7 . APOBEC-signature mutagenesis has been linked with the activity of two members of the APOBEC3 subfamily-APOBEC3B (A3B) and APOBEC3A (A3A) 3, 8, 9 . All APOBEC3 proteins (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) are encoded by genes located within a 200-kb APOBEC3 genomic cluster on chromosome 22q13.1.
A r t i c l e s
Somatic mutations of a specific type (substitutions of C with T or G in TCA or TCT motifs) have been described in many tumors as APOBECsignature mutations [1] [2] [3] [4] [5] . These mutations are generated by the cytidine deaminase activity of proteins belonging to the apolipoprotein B mRNA editing enzyme, catalytic-polypeptide-like (APOBEC) family 6, 7 . APOBEC-signature mutagenesis has been linked with the activity of two members of the APOBEC3 subfamily-APOBEC3B (A3B) and APOBEC3A (A3A) 3, 8, 9 . All APOBEC3 proteins (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) are encoded by genes located within a 200-kb APOBEC3 genomic cluster on chromosome 22q13.1.
Two common germline variants in this region have been associated with cancer risk. The first of these variants is SNP rs1014971, which is located upstream of the APOBEC3 cluster 10 . This SNP has been associated with risk for bladder cancer in a genome-wide association study (GWAS) in individuals of European ancestry 10 and replicated in a Japanese study 11 . The second of these variants is a 30-kb deletion that fuses the coding region of APOBEC3A with the 3′ UTR of APOBEC3B, resulting in the loss of APOBEC3B and the gain of a chimeric APOBEC3A-APOBEC3B transcript (APOBEC3AB) that encodes A3A 12 . Both APOBEC3A and APOBEC3AB transcripts encode A3A enzyme, but the presence of the 3′UTR from APOBEC3B increases the stability of the APOBEC3AB transcript and leads to increased A3A levels in vitro 13 . The deletion has been associated with increased risk for breast and ovarian cancers [14] [15] [16] , as well as enrichment with APOBEC-signature mutations in breast tumors 8, 17 .
Because APOBEC-signature mutations have been described in both bladder and breast tumors 2, 3 , and associations with germline variants within the APOBEC3 region have been reported for these cancers, we explored whether germline variants in this region are associated with APOBEC mutagenesis. We also tested some environmental exposures that might induce APOBEC3A and APOBEC3B expression and contribute to APOBEC mutagenesis.
RESULTS
Fine-mapping and association analysis of the APOBEC3 region SNP rs1014971 is the original GWAS signal within the 22q13.1 region detected for bladder cancer risk at a genome-wide significance level (P = 8.4 × 10 −12 ) 10 . This SNP is located in an intergenic Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors region, 66 kb upstream of CBX6 and 20 kb upstream of APOBEC3A, which is the first gene in the APOBEC3 gene cluster. We performed fine-mapping analysis of the region in the combined bladder cancer NCI-GWAS set of individuals of European ancestry (5,832 cases and 10,721 controls) 10, 18 . The strongest associations were detected for three correlated SNPs (all with r 2 = 1.0)-the original GWAS SNP, rs1014971, and two additional SNPs, rs1004748 and rs17000526 ( Fig. 1 and Supplementary Table 1 ). There was no evidence for a significant independent signal after adjusting for rs1014971 (Supplementary Table 1 ). On the basis of data generated by the Breast Cancer Association Consortium (BCAC) 19 , these three SNPs were also associated with breast cancer risk, having allele effects in the same direction as in bladder cancer, although the association was weaker and only present in women with estrogen receptor (ER) + breast tumors (in Europeans, odds ratio (OR) = 1.03, P = 0.0072 for the rs1014971[T] allele; Supplementary Note).
The APOBEC3AB deletion has been significantly associated with increased breast cancer risk [14] [15] [16] ; thus, we tested the association of this deletion with bladder cancer risk. Deletion status was determined directly by a copy number variation (CNV) assay or indirectly by TaqMan genotyping of SNP rs12628403 (Supplementary  Table 2 and Supplementary Note), which has been strongly associated with breast cancer risk in a Chinese population 16 . We confirmed rs12628403 to be the only available proxy for the CNV with D′ = 1.0, r 2 = 1.0 in Europeans and Japanese and D′ = 1.0, r 2 = 0.95 in Chinese, although it was not a proxy in Africans, in whom the CNV has a frequency of 4.2% while rs12628403 is monomorphic (in 1000 Genomes Project populations; Supplementary  Fig. 1 ). Neither the CNV nor rs12628403 can be imputed on the basis of existing 1000 Genomes Project data ( Supplementary  Fig. 2 ) and thus require genotyping.
The deletion was more common in controls than in cases, both in individuals of European ancestry and Japanese (Table 1) ; the meta-analysis results showed significantly reduced bladder cancer risk in carriers of the deletion (OR = 0.85, 95% confidence interval (CI) = 0.74-0.97, P = 0.013; Table 1 ). However, association with the deletion disappeared after adjustment for the effect of rs1014971 (Supplementary Table 3) ; haplotype analysis of the two variants also showed that association was driven by rs1014971 (Table 2) . Thus, the effect of the deletion on bladder cancer risk seems to be subsumed by the effect of rs1014971.
SNP rs17000526 is associated with APOBEC3B expression in tumors
We analyzed data generated by The Cancer Genome Atlas (TCGA) 20, 21 , focusing on a 400-kb region that included the APOBEC3 gene cluster and flanking genes. We evaluated expression of each gene isoform within this region in relation to SNP rs17000526 (a TCGA-genotyped proxy for rs1014971, r 2 = 1.0). Only expression of the major APOBEC3B isoform (UCSC transcript uc003awo.1) was significantly associated with rs17000526 in bladder and breast tumors, with higher expression observed in carriers of the A risk allele (see Supplementary Tables 4  and 5 for exploratory analysis adjusting only for age, sex, and ancestry). In an expanded multivariate linear regression analysis of APOBEC3B expression, we evaluated the effects of SNP rs17000526, age, sex, ancestry, DNA methylation of a CpG site found to be significantly associated with APOBEC3B expression (Supplementary Table 6 ), and somatic copy number alterations (CNAs). This analysis showed significant association of SNP rs17000526 with APOBEC3B expression, with per-allele β coefficient = 0.25, P = 5.37 × 10 −4 for bladder tumors (Fig. 2a,b) and per-allele β coefficient = 0.19, P = 5.99 × 10 −3 for breast tumors (Fig. 2c,d ).
SNP and APOBEC3A/APOBEC3B expression predict APOBEC mutagenesis Next, we analyzed APOBEC mutagenesis using two variables-total counts of APOBEC-signature mutations and APOBEC mutagenesis pattern-using public data sets available through the Firehose portal (Online Methods and Supplementary Data 1). The APOBEC Figure 1 Fine-mapping analysis of the 22q13.1 region for association with bladder cancer risk. The plot is based on the combined NCI-GWAS1 and NCI-GWAS2 set, which includes 2,301 imputed and 142 genotyped SNPs for 5,832 bladder cancer cases and 10,721 controls of European ancestry. The results are shown for a 400-kb region centered on GWAS SNP rs1014971, the same region as was used for the expression quantitative trait locus (eQTL) analyses of TCGA data. The left y axis corresponds to the −log 10 (P value) for association with bladder cancer risk; the right y axis corresponds to the recombination map of the region, with recombination hotspots connected by the line. The SNPs with the strongest signals are presented as colored diamonds; all other SNPs are presented as circles.
The position of the deletion is marked by a gray rectangle; the APOBEC3A-APOBEC3B (APOBEC3AB) deletion isoform is labeled along the gene track. A r t i c l e s A r t i c l e s mutagenesis pattern is a more stringent definition that represents statistically significant enrichment with APOBEC-signature mutations over random mutagenesis 3, 22 . Most TCGA bladder tumors with APOBEC-signature mutations (347/395), but only one-quarter of breast tumors (224/977), showed the APOBEC mutagenesis pattern. Although analysis of the two metrics generated very similar results, we provide them side by side for comparison. In bladder tumors, SNP rs17000526 was strongly associated with APOBEC-signature mutations (β coefficient = 0.18, P = 1.92 × 10 −5 ; Fig. 2e ,f) and APOBEC mutagenesis pattern (β coefficient = 0.23, P = 3.17 × 10 −5 ; Fig. 2i,j) . Among the 14 known bladder cancer GWAS signals, the association with APOBEC-signature mutations was specific to rs17000526 (Supplementary Table 7 ). However, rs17000526 was not associated with APOBEC mutagenesis in breast tumors (Fig. 2g,h,k,l) . In bladder tumors, rs17000526 and expression of major isoforms of APOBEC3B and APOBEC3A were significant independent predictors of both metrics of APOBEC mutagenesis (APOBEC-signature mutations and APOBEC mutagenesis pattern), with β coefficients of 0.15 and 0.20 for the SNP, 0.14 and 0.17 for APOBEC3B expression, and 0.05 and 0.10 for APOBEC3A expression, respectively (Fig. 2m,n) . In breast tumors, Asian ancestry, expression of the major APOBEC3A isoform, and expression of the APOBEC3AB deletion isoform (corresponding to APOBEC3AB germline deletion) were significant independent predictors of both metrics of APOBEC mutagenesis, with β coefficients of 0.29 and 0.35 for Asian ancestry, 0.17 and 0.15 for APOBEC3A expression, and 0.13 and 0.11 for APOBEC3AB deletion, respectively (Fig. 2o,p) . Expression levels of APOBEC3C, APOBEC3F, and APOBEC3H isoforms were less predictive, and all other APOBEC3 isoforms were not predictive of APOBEC mutagenesis in bladder and breast tumors (Supplementary Tables 8 and 9 ).
SNP rs1014971 shows allele-specific protein binding
The three linked SNPs associated with bladder and breast cancer risk-rs1014971, rs17000526, and rs1004748-are located within a 2-kb genomic region 20 kb upstream of APOBEC3A. Previously, this region has been reported as a putative long-distance enhancer that interacts with the APOBEC3B promoter in lymphoblastoid and bone marrow (CD34 + ) cells 23 . Because variants within the APOBEC3B promoter were not associated with breast cancer 24 , mRNA expression and cancer risk could be affected by variation within the long-distance enhancer region. In silico functional annotation of the 2-kb region showed enrichment of functional marks characteristic of enhancer activity around rs17000526 (Fig. 3a) . However, electrophoretic mobility shift assays (EMSAs) did not show allele-specific binding patterns for rs1004748 and rs17000526 with nuclear protein extracts from two bladder cancer cell lines (HT-1376 and RT-4) and the breast cancer cell line MCF-7 (Fig. 3b) . In contrast, in the bladder cancer cell lines, binding was exclusive for the rs1014971[T] risk allele, whereas in the breast cancer cell line some binding was also observed for the rs1014971[C] non-risk allele (Fig. 3b) . This binding pattern for rs1014971 was validated in three additional cell lines (Supplementary Fig. 3 ). This result is in line with the stronger association of this SNP with APOBEC3B expression in bladder in comparison to breast tumors (β coefficient = 0.25 versus 0.19, respectively; Fig. 2a,c) and stronger estimated effect of this SNP for risk of bladder cancer (OR = 1.13) 18 as compared to ER + breast cancer (OR = 1.03) (Supplementary Note).
APOBEC3 genes can be induced by environmental factors APOBEC3 genes are ubiquitously expressed in many human tissues and cell types 25 ( Supplementary Fig. 4 ), but their endogenous baseline expression levels are likely to be non-genotoxic, as has been demonstrated for A3A 26 . APOBECs are mutagenic when overexpressed in vitro [26] [27] [28] , but it is unclear what induces their endogenous expression under physiological conditions. Some APOBECs can be induced as part of the interferon-driven innate immune response to viral pathogens, for example, induction of A3G that restricts HIV 29 . Induction of APOBEC3A and APOBEC3B by interferons has also been demonstrated 30, 31 .
To test whether APOBEC3A, APOBEC3B, and APOBEC3G (used as a control) can be induced as a part of interferon response, we infected three bladder (HT-1376, HTB-9, and RT-4) and three breast cancer (MCF-7, MDA-MB-231, and T-47D) cell lines with Sendai virus (SeV), which is a model nonlytic RNA virus that induces a robust interferon response in diverse human cell types 32 . These cell lines were chosen because they represent some of the major clinical subtypes of bladder and breast tumors (Online Methods). As expected for response to an RNA virus 33, 34 , we observed strong induction of many known interferonstimulated genes (ISGs), including APOBEC3G (Supplementary Table 10 ). There was striking induction of APOBEC3A (by 32-fold, 51-fold, and 12,000-fold) in the three breast cancer cell lines, in contrast to more moderate induction (4-fold, 5-fold, and 167-fold) in the three bladder cancer cell lines (Fig. 4 and Supplementary Figs. 5 and 6 ). However, Haplotypes include SNP rs1014971 with alleles T and C and the APOBEC3AB deletion with alleles I (insertion) and D (deletion). Haplotype effect: P, protective; R, risk (based on association with bladder cancer risk). The haplotype in which the risk-conferring effect of the rs1014971[T] allele could be neutralized by the deletion allele (haplotype 4) is uncommon in both populations (~1-1.5% frequency in Europeans and Japanese). The haplotype with the protective rs1014971[C] allele and the deletion allele (haplotype 3) is uncommon in Europeans (~5%) and common in Japanese (~25%), but the protective effect of this haplotype is similar to that of the haplotype with the protective allele of rs1014971 alone (haplotype 2). Ref, reference group; n, number of chromosomes.
a Odds ratios and P values are adjusted for age, sex, smoking status, and study site (SBCS, Spain; PLCO, United States).
A r t i c l e s APOBEC3B was only induced by 0.84-to 1.75-fold in SeV-infected bladder cancer cells and by 0.15-to 4.89-fold in breast cancer cells, possibly because of the relatively high APOBEC3B expression already present at baseline ( Fig. 4 and Supplementary Figs. 5 and 6).
APOBECs introduce mutations by editing single-stranded DNA (ssDNA), which is abundant under conditions associated with DNA damage, repair, and replication 35 , but it is unknown whether DNA damage can induce expression of APOBEC3 genes. To test this, we treated cells with bleomycin, a DNA-damaging drug known to induce DNA breaks 36 ; expression analysis confirmed that an interferon response was not induced by this treatment (Supplementary Table 10 ). Both APOBEC3A and APOBEC3B were induced in most cell lines, but the effect was more robust for APOBEC3B, especially in bladder cancer cell lines ( Fig. 4 and Supplementary Figs. 5 and 6 ). In all cell lines, APOBEC3A expression was much lower than that of APOBEC3B at baseline (Fig. 4) . However, viral infection in breast A r t i c l e s cancer cells strongly induced APOBEC3A, increasing its expression levels above those for APOBEC3B. APOBEC3G was induced in some cell lines by both treatments (Fig. 4 and Supplementary Figs. 5 and 6), but A3G is a cytoplasmic enzyme that does not edit TC motifs 3 and thus is not expected to generate APOBEC-signature mutations.
APOBEC mutagenesis is the best predictor of survival
Multivariate analysis showed that survival of TCGA patients with bladder cancer was most significantly predicted by tumor stage and APOBEC mutagenesis, whereas treatment (yes/no) was not a significant predictor (Supplementary Table 11 ). Survival was improved by more than twofold (P = 2.41 × 10 −4 ) in patients with mutation counts above versus below median levels (73 APOBEC-signature mutations and 49 mutagenesis pattern mutations; Fig. 5a,b) . Significant correlation of survival with APOBEC mutagenesis is also presented in Firehose (Online Methods). The effect of the SNP was in the same direction, with individuals homozygous for the bladder cancer risk allele having longer survival (P = 0.067; Fig. 5 and Supplementary Table 11) . Association of rs17000526 with survival was fully explained by APOBEC mutagenesis, although adjustment for rs17000526 had only a moderate effect (Supplementary Table 11 ), suggesting that many factors, including rs17000526, contribute to APOBEC mutagenesis. We also evaluated the effects of all APOBEC3 isoforms on survival. The effect of APOBEC3B expression was comparable to that of rs17000526 and was similar in treated and untreated patients (β coefficient = −0.26 and −0.27, respectively), whereas the effect of APOBEC3A expression was much stronger in treated than in untreated patients (β coefficient = −0.41 and 0.05; Supplementary Table 11 ). This suggests that mutagenesis caused by A3B may represent a genetically regulated mechanism contributing to cancer initiation, whereas mutagenesis caused by A3A may represent events occurring in tumors and be influenced by tumor-specific environment, including treatment. Some isoforms of APOBEC3D and APOBEC3H significantly predicted survival, but only in treated patients, in line with a recent analysis of survival in 73 patients with bladder cancer treated with adjuvant platinum-based therapy 37 . It is unclear whether these effects are related to APOBEC mutagenesis or the inflammatory microenvironment and infiltration with PD-L1-expressing mononuclear cells observed for these tumors 37 .
For breast cancer, there was a similar but non-significant trend for better survival in patients with ER + tumors and high APOBECsignature mutation counts; there was also association between survival and rs17000526, but only in ER − breast tumors ( Supplementary  Fig. 7) . Of APOBEC3A and APOBEC3B transcripts, only expression of APOBEC3AB was significantly associated with survival, with ER + carriers of the germline deletion having significantly worse survival (β coefficient = 0.64, P = 0.006; Supplementary Fig. 7) .
Increased APOBEC3B expression has been observed in breast tumors with somatic mutations in the tumor-suppressor gene TP53, which was explained by improved survival of cells with high APOBECsignature mutation loads when TP53 is inactivated 4 . TP53 is the most commonly mutated gene in bladder tumors, and we observed that TP53 mutations were significantly enriched in the group with an AA genotype at rs17000526 (Supplementary Table 12) . The same trend was observed for mutations in PIK3CA, the fifth most commonly mutated gene in bladder tumors (Supplementary Table 13) , and TP53 mutations in ER − breast tumors (Supplementary Table 14) . However, adjustment for the presence of TP53 mutations did not significantly affect the association between rs17000526, APOBECsignature mutations, and survival of patients with bladder or breast cancer (Supplementary Tables 12 and 14) .
DISCUSSION
Although somatic mutations emerge on the background of germline variants, some of which are associated with increased predisposition to cancer, the relationships between germline and somatic mutations are largely unknown. Mutation profiles within genomic regions harboring GWAS signals have been explored for a range of cancers, but genes with common germline risk variants are not enriched for somatic mutations 38 , unlike the highly penetrant familial cancerrelated genes 39 . However, our study shows that common germline Red boxes highlight allelespecific differences for interaction of SNP rs1014971 with nuclear cell extracts from bladder and breast cancer cell lines. Competition assays were performed with a 100-fold excess of unlabeled specific (self) and non-specific (opposite-allele) probes. In both bladder cancer cell lines, binding was observed only for the risk-associated rs1014971[T] allele, whereas in the breast cancer cell line binding was also detected for the non-risk rs1014971[C] allele, although it was weaker than for the riskassociated rs1014971[T] allele. For SNPs rs17000526 and rs1004748, no distinct allele-specific pattern of binding was observed.
A r t i c l e s variants within the APOBEC3 region that affect expression of APOBEC3s, the mutation-causing enzymes, are associated both with cancer predisposition and global somatic mutation profiles.
Bladder cancer risk is increased in carriers of the rs1014971[T] allele, and we suggest that this could be because of its association with increased expression of APOBEC3B and generation of APOBECsignature mutations in bladder tissue. Although the functional effect of the APOBEC3AB deletion that eliminates APOBEC3B and creates the A3A-encoding APOBEC3AB transcript could be substantial, its genetic association with bladder cancer risk was subsumed by SNP rs1014971. In contrast, breast cancer risk is only moderately associated with SNP rs1014971 but strongly with the APOBEC3AB deletion, and the enrichment with APOBEC-signature mutations is strongly associated with expression of APOBEC3A and APOBEC3AB, but not APOBEC3B.
We also show that expression of APOBEC3A and APOBEC3B is inducible by environmental exposures. Treatment with a DNAdamaging drug, bleomycin, induced APOBEC3B in all cell lines tested, with the effect being most robust in bladder cancer cell lines. DNA damage as a result of exposure to environmental carcinogens is specifically important for bladder cancer because of direct contact of bladder epithelium with bioactive metabolites that accumulate in urine. Exposures to occupational and environmental carcinogens strongly increase the risk for bladder cancer, and germline susceptibility variants may modify this risk 40 . SNP rs1014971 has already been shown to significantly modify bladder cancer risk caused by tobacco smoking, the most well-known environmental risk factor 41 , and our results suggest that this could be through regulation of APOBEC3B expression by this SNP contributing to APOBECsignature mutagenesis.
In contrast, APOBEC3A expression was uniformly induced by viral infection, with 30-to 12,000-fold induction in breast cancer cell lines and 4-to 167-fold induction in bladder cancer cell lines. This range of induction suggests additional cell-type-specific factors that may affect sensitivity to different environmental exposures. APOBEC3AB deletion has been associated with an interferon-induced inflammatory gene expression profile in breast tumors 42 , supporting our conclusions that APOBEC3A (and APOBEC3AB) is part of this profile. Although in our experiments this expression was induced by an RNA virus, in vivo it might be induced by diverse stimuli that result in activation of interferon response.
APOBEC3 activity has also been associated with hypermutation of some carcinogenic DNA viruses, such as human papillomavirus (HPV) 30, 31, 43 and hepatitis B virus (HBV) 30, 44 . APOBEC mutagenesis contributes to non-cytolytic clearance of these viruses but can also result in increased viral diversity and APOBEC-signature mutagenesis in surrounding tissues, contributing to tumorigenesis. Response to DNA viruses might depend on tissue-specific repertoires of APOBECs and cellular mechanisms induced by particular infections, such as interferon-stimulated antiviral response, virally induced DNA damage, or some other specific mechanisms that need to be explored for each tissue and viral infection individually.
We found that in bladder tumors SNP rs17000526, APOBEC3B, and APOBEC3A expression, whereas in breast tumors APOBEC3AB deletion and APOBEC3A expression are significant independent predictors of APOBEC mutagenesis. We speculate that mRNA expression A r t i c l e s may capture both the germline-regulated and environmentally inducible components that contribute (or have contributed in the past) to accumulation of APOBEC-signature mutations through the tumor history. At the same time, the SNP may represent germline-regulated expression levels that would be relevant at the time of mutagenesis but might not be detectable by the snapshot expression analysis in excised tumors. Some other factors that might be relevant for APOBEC mutagenesis, such as environmental exposures, are impossible to quantify (both the magnitude and timing) and other factors are unknown. On the basis of currently available data, we suggest that a combination of germline variants rs17000526 and APOBEC3AB deletion and mRNA expression of APOBEC3B and APOBEC3A in tumors might provide better prediction of APOBEC mutagenesis than each of these variables alone. Although expression of APOBEC3 genes (APOBEC3A, APOBEC3B, and APOBEC3AB, specifically) is a likely prerequisite for APOBECsignature mutagenesis, some factors may modify the outcome of this expression. For example, loss of FHIT protein was shown to create DNA breaks that provide substrate for APOBEC mutagenesis; TCGA lung adenocarcinoma tumors with high APOBEC3B expression and FHIT loss had higher APOBEC mutagenesis than tumors with high APOBEC3B expression but without FHIT loss 45 .
Interestingly, TCGA patients with bladder cancer with increased APOBEC mutagenesis (more than 73 APOBEC-signature mutations or more than 49 APOBEC-mutagenesis-pattern mutations) had significantly improved survival. The SNP rs17000526 showed a similar although less significant trend with each risk allele. Considering that all bladder tumors in TCGA are of the most aggressive, muscle-invasive type, this might be a clinically significant finding that requires careful follow-up. Increased mutation loads, especially in DNA repair genes, were associated with response to neoadjuvant cisplatin-based treatment of muscle-invasive bladder cancer; this was attributed to the inability of cancer cells to recover after treatmentinduced DNA damage 46 . We observed higher TP53 and PIK3CA mutation rates in bladder tumors from patients homozygous for the rs17000526[A] allele. Tumors with higher mutation burden are also more likely to be targeted by immune surveillance 47 and respond to PD-1 checkpoint inhibitors 48 . A SNP (rs1014971 or its proxy rs17000526) by itself might not be informative enough for clinical use, but it should be combined with other clinical, genetic and molecular markers and tested for clinical utility for the management of bladder cancer. The current analysis in TCGA samples is based on whole-exome sequencing and it remains to be seen whether targeted exome sequencing, which is becoming common in the clinic, can provide sufficient and clinically relevant information about APOBEC mutagenesis.
In conclusion, our work shows how functional germline variants and environmental exposures may affect somatic mutations and clinical outcomes. We propose (Fig. 6 ) that even transient exposures to relevant environmental factors might induce APOBEC3A or APOBEC3B expression above genotoxic levels and initiate tumorigenesis in a tissue-specific manner in the right cellular environment where ssDNA is available; germline APOBEC3 variants might affect both the baseline and threshold levels of APOBEC3A and APOBEC3B expression. Genomic instability and DNA breaks acquired during tumor development could provide a source of ssDNA independent of external environmental exposures, further stimulate APOBEC3 expression, and fuel APOBEC-mediated mutagenesis and tumor evolution. On the other hand, more efficient immune surveillance due to neoantigens and synthetic lethality of tumor cells can contribute to improved survival for patients with higher APOBEC mutagenesis. Because APOBEC-signature mutagenesis has been reported in 16 of 30 tumor types analyzed by TCGA 2 , further work is needed to explore the relationships between germline variants Expression of APOBEC3A, APOBEC3AB, and APOBEC3B transcripts generating A3A and A3B enzymes can be induced by environmental factors such as DNA-damaging agents and viral infections that activate interferon-stimulated innate immune response. SNP rs1014971 shows important associations, predominantly for bladder cancer, with increased cancer risk, APOBEC3B expression, APOBEC mutagenesis, and survival, while APOBEC3AB deletion shows associations with breast cancer. (c) Hypothesis for the combined role of germline and environmental factors in APOBEC mutagenesis. In normal tissues, A3A and A3B levels increase with the number of risk alleles of germline variants (SNP rs1014971 or the APOBEC3AB deletion) but are still below the genotoxic threshold. Exposures to DNA-damaging agents or viral infections can induce A3A and A3B levels above the genotoxic threshold, especially in individuals with germline risk variants. Mutagenesis and tumor initiation can occur if ssDNA is available endogenously (DNA replication and repair) or is generated by DNA-damaging exposures.
In the tumor microenvironment, ssDNA can be available from DNA damage due to genomic instability and cancer therapies; continuous DNA damage maintains high A3B and A3A levels above the genotoxic threshold. Depending on cancer and treatment type, high APOBEC mutagenesis may be associated with improved or decreased survival.
can be relevant for mRNA expression. Somatic changes in tumor tissue might have resulted in aberrant DNA methylation or CNA 53 ; thus, we additionally adjusted for the effects of these factors on expression levels. DNA methylation levels for CpG sites upstream of APOBEC3B were log 10 transformed (this is an optional step), quantile normalized 51, 52 , and tested for correlation with APOBEC3B expression. The CpG site with the strongest effect on expression, as measured by the β coefficients and P values, was used for adjustment in subsequent analyses (Supplementary Table 6 ).
Analysis of APOBEC mutagenesis. APOBEC-signature mutation data for TCGA samples were acquired from the Broad Institute Genome Data Analysis Center (GDAC) 50 Data 1) . In this file, we used two variables: the 'tCw_to_G+tCw_to_T' variable, which represents total counts of APOBEC-signature mutations, and the ' APOBEC_MutLoad_MinEstimate' variable, which accounts for statistical significance of enrichment and represents the APOBEC mutagenesis pattern per sample. This variable is more stringent, as many samples were not enriched at a statistically significant level and were classified as negative for APOBECsignature mutations. Mutation counts were log 10 transformed to improve the normality of distribution. A P value of 0.05 was used as a threshold for significance, unless specified otherwise, and all tests were two-sided. The Bonferroni multiple-comparisons significance level is reported where appropriate. We also downloaded from Firehose and analyzed an updated data set for APOBEC mutagenesis (stamp analyses__2016_01_28); the results were very similar (data not shown) to those generated for the April 2015 data set reported here.
Mutation analysis of selected genes in TCGA. Data for functionally relevant somatic mutations 54 in some frequently mutated genes generated using MutSig2CV were downloaded from Broad Institute Firebrowse. The mutation data for each gene were obtained from the 'aggregate analysis features' tab from file _-TP.samplefeatures.txt using column "SMG_mutsig.2CV_gene" (provided in Supplementary Data 1) . We evaluated the distribution of mutations in bladder tumors in a panel of genes-TP53, RB1, ELF3, TSC1, PIK3CA, RHOB, CDKN2A, ARID1A, ZFP36L1, CDKN1A, ATM, and FGFR3-and for TP53 in breast tumors in relation to rs17000526 genotype groups. Statistical significance was evaluated on the basis of 2 × 3 χ 2 tests, without adjustment for any other variables.
Survival analysis. Survival analysis was performed using TCGA data. Overall survival was defined as months until patient death or last follow-up. P values and hazard ratios were derived from multivariate Cox regression models that included age, sex (excluded in breast cancer analysis), and tumor stage as core variables, and additional variables such as SNP rs17000526, APOBEC mutagenesis, or mRNA expression of APOBEC3 genes. For APOBEC mutagenesis, survival analysis was performed using mutation counts as continuous variable or in groups-quartiles or custom defined. Treatment information (yes/no for any neoadjuvant or adjuvant treatment) was used in additional analyses. Univariate survival analysis in relation to APOBEC mutagenesis is also presented in Firehose http://dx.doi.org/doi:10.7908/C1G44PGV and later version http://dx.doi.org/doi:10.7908/C15T3JTD (see URLs).
In silico functional annotation. Annotation was performed using resources of ENCODE (available from UCSC Genome Browser) and HaploReg v4. Analysis included data for ChIP-seq for different histone marks, CTCF motifs, DHSs, FAIRE-seq peaks, and transcription factor binding sites from different cell lines.
HaploReg analysis was performed using default settings for a European population and included annotation for enhancers, H3K4me1, and H3K27ac.
Electrophoretic mobility shift assays. Oligonucleotides (primers) for the three SNPs were designed on the basis of reference genomic sequences from dbSNP (see URLs) and purchased from Life Technologies (Supplementary Table 20) . Primers were labeled with biotin using a 3′-end labeling kit (Pierce), and corresponding labeled forward and reverse primers were annealed to generate double-stranded allele-specific probes. The efficiency of biotin labeling was confirmed to be similar for each probe pair by dot blot tests with serial dilutions. EMSA reactions were performed with a LightShift Chemiluminescent EMSA kit (Thermo Scientific). Nuclear extracts were prepared from three bladder cancer cell lines (HT-1376, RT-4, and HTB-9) using a nuclear extraction kit (Active Motif), and commercially available nuclear cell extracts were purchased from Active Motif for breast cancer cell lines (MCF-7, MDA-MB-231, and T-47D). Similar amounts of all nuclear extracts (10 µg) were used for reactions. For competition assays, unlabeled specific (self) and non-specific (oppositeallele) probes were used at a 100-fold excess. Glycerol, NP-40, and magnesium chloride were used to optimize the reactions. The reactions were incubated for 30 min at room temperature, and protein complexes were immediately resolved on 6% DNA retardation gels (Invitrogen) for 1.5 h at 100 V and transferred to Biodyne B nylon membranes (Pierce) for 40 min at 380 mA. Crosslinking was performed using the Stratagene Stratalinker UV Crosslinker 2400, and membranes were probed using the Chemiluminescent Nucleic Acid Detection Module (Pierce).
Treatment with DNA-damaging drug and viral infection. Bleomycin (sulfate) was purchased from Cayman Chemicals. Bladder and breast cancer cells grown in six-well plates were treated in triplicate or quadruplicate with bleomycin (25 µg/ml) for 5 or 24 h. Stocks of SeV strain Cantell were purchased from Charles River Laboratories. SeV is a single-strand RNA murine parainfluenza virus that infects human cells and induces a robust antiviral interferon response that quickly controls infection 32 . Bladder and breast cancer cells were infected in triplicate or quadruplicate with SeV (7.5 × 10 5 CEID 50 /ml, where CEID 50 is the chicken embryo infectious dose 50%) for 1 h, washed with PBS, and then collected at 0, 3, 6, and 12 h after infection.
qRT-PCR analysis. Total RNA for all experiments was isolated with an RNeasy kit with on-column DNase I treatment (Qiagen). RNA quantity and quality were evaluated by NanoDrop 8000 (Thermo Scientific). cDNA was prepared from equal amounts of total RNA for each sample (10 ng per 5-µl reaction) with the RT 2 first-strand cDNA kit and random hexamers with an additional DNA removal step (Qiagen). SeV loads were evaluated by qRT-PCR with virus-specific primers for SeV defective-interfering (SeV-DI) RNA (Supplementary Table 20) . Expression of APOBEC3A, APOBEC3B, and APOBEC3G and endogenous controls GAPDH, ATCB, and PPIA was measured in the same cDNA with TaqMan expression assays: Hs00377444_m1 for APOBEC3A, Hs02564469_s1 for APOBEC3B, Hs01043989_m1 for APOBEC3G, and 4326317E for GAPDH, 4352935 for ATCB, and 4326316E for PPIA (Life Technologies). Reactions were performed in four technical replicates on QuantStudio 7 (Life Technologies) using SYBR Green Rox qPCR Mastermix (Qiagen) or TaqMan Gene Expression buffer (Life Technologies); water and genomic DNA were used as negative controls for all assays. For antiviral pathway expression analysis, qRT-PCR mRNA expression analysis was performed using the SYBR Green Antiviral Response qRT-PCR array (Qiagen). The plates included 88 expression assays for target genes, as well as positive, negative, and endogenous normalization controls (Supplementary Table 10 ). Reactions included 10 ng of total DNase-treated RNA in a 10-µl volume and were carried out for two biological replicates from each experimental condition. Expression was measured in C t values (PCR cycle at detection threshold), which are distributed on a log 2 scale. Expression of APOBEC3 genes was normalized by the mean of endogenous controls (GAPDH, ACTB, and PPIA). Differences in expression were calculated according to the relative quantification method, as ∆C t = C t (control) − C t (target).
